J

Johnson & Johnson

Makes prescription drugs and medical devices

Territory Manager - Oncology

Full-TimePosted on 10/22/2026Deadline 10/29/26
$85.7k - $135.7k+ Discretionary performance bonus
Senior
Bachelor's
Moncton, NB, Canada+1 moreMore locations: Halifax Regional Municipality, NS, Canada
In PersonWork is hybrid between virtual interactions and in-field HCP visits; over 70% of time is spent in HCP offices or hospitals, with business travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 5 years of business or sales experience is required.
  • Ability to diagnose customer needs using clinical and practice insights, tailor evidence-based recommendations, and persuade healthcare professionals to adopt solutions aligned with patient and business outcomes.
  • Ability to segment accounts, set priorities and measurable goals, and implement adaptive, resource-aligned plans to drive sales, access, and market share within the territory.
  • Up-to-date understanding of relevant disease states, product data, and treatment pathways to educate customers, support clinical decision-making, and identify when escalation to Medical Affairs is needed.
  • Ability to use customer relationship management systems and channel analytics to plan, document, and optimize outreach across in-person and digital channels, and turn quantitative and qualitative data into actionable territory decisions.
  • Ability to develop trusted relationships with healthcare professionals and internal stakeholders, influence decisions without formal authority, and mobilize cross-functional support for customer-centric solutions.
  • Adherence to regulatory, company, and pharmacovigilance requirements, including timely reporting of adverse events or complaints and ethical conduct in interactions.
  • Ability to communicate complex clinical information clearly and persuasively to diverse audiences and deliver presentations in virtual and face-to-face settings.
  • Ability to lift or move objects weighing more than 25 pounds and lift a box of marketing materials weighing less than 10 pounds.
  • Valid driver's license and good driving history.
  • Ability to use Excel, PowerPoint, Word, Outlook, customer relationship management systems, a tablet, and a web camera.
Responsibilities
  • Develop and implement business plans and sales strategies aligned with company and brand-specific customer objectives.
  • Represent Johnson & Johnson Innovative Medicine to healthcare providers, face to face and virtually, to achieve sales forecasts.
  • Cultivate relationships with key decision-makers and use compliant, consultative, and persuasive selling skills to increase access and gain product support.
  • Build internal and external networks and develop collaborative solutions based on knowledge of the healthcare ecosystem.
  • Use the iConnect/customer relationship management platform to plan and execute calls, omnichannel email and suggestion deployment, and educational-event inputs.
  • Use product and clinical therapeutic knowledge to influence decision-making that benefits patients.
  • Research the competitive landscape and adapt strategies to build customer loyalty.
  • Use field insights to identify healthcare professionals' education needs, align those needs with Medical Education Manager-led educational platforms, and organize and execute regional learning activities.
  • Lead accountability for compliance with customer relationship management deployment metrics, healthcare compliance, expenses, samples, training procedures, and timelines.
  • Report product complaints, adverse events, adverse drug reactions, special situations, and product quality complaints to the Local Medical Safety Canada or Local Pharmacovigilance Team within one business day, or no later than calendar day three in the event of a public holiday.
  • Prepare for and participate in regularly scheduled sales-team and marketing-team calls and company meetings.
  • Complete required prework and training for national business meetings and regional meetings and actively participate in them.
  • When selected, attend, prepare for, and actively participate in medical conferences.
  • Use quantitative data, qualitative data, and available tools to assess territory business conditions and performance.
  • Build awareness of high-value customers and profile the customer base according to brand segmentation strategy; target activities and resources across priority segments.
  • Develop and execute a compliant, customer-centric territory business plan aligned with company objectives, evaluating progress and modifying the plan based on marketplace knowledge and customer needs.
  • Develop compliant strategies to increase customer access and commitment, adapting established approaches to improve results and efficiency.
  • Participate in best-practice sharing discussions with colleagues.
  • Perform occasional work on company workstream projects.
Desired Qualifications
  • Preferred areas of study include science, business, or a health-related field.
  • Related industry experience in healthcare, pharmaceuticals, or medical devices is preferred.
  • Commitment to learning emerging technologies such as artificial intelligence through exploration, iteration, and applying new tools over time.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.